TY  - GEN
AU  - Balcer,L J
AU  - Galetta,S L
AU  - Calabresi,P A
AU  - Confavreux,C
AU  - Giovannoni,G
AU  - Havrdova,E
AU  - Hutchinson,M
AU  - Kappos,L
AU  - Lublin,F D
AU  - Miller,D H
AU  - O'Connor,P W
AU  - Phillips,J T
AU  - Polman,C H
AU  - Radue,E-W
AU  - Rudick,R A
AU  - Stuart,W H
AU  - Wajgt,A
AU  - Weinstock-Guttman,B
AU  - Wynn,D R
AU  - Lynn,F
AU  - Panzara,M A
TI  - Natalizumab reduces visual loss in patients with relapsing multiple sclerosis
SN  - 1526-632X
PY  - 2007///0511
KW  - Adolescent
KW  - Adult
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Brain
KW  - drug effects
KW  - Contrast Sensitivity
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Multiple Sclerosis, Relapsing-Remitting
KW  - complications
KW  - Natalizumab
KW  - Neurologic Examination
KW  - methods
KW  - Placebos
KW  - Predictive Value of Tests
KW  - Treatment Outcome
KW  - Vision Tests
KW  - Vision, Low
KW  - drug therapy
KW  - Visual Acuity
KW  - Visual Pathways
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1212/01.wnl.0000259521.14704.a8
ER  -